Does accountability legislation threaten integrity of U.S. research enterprise?

Mildred Dresselhaus coauthored a report to be released Feb. 17. National Academy of Sciences (NAS) President Bruce M. Alberts was so concerned by the accountability provision buried in last year's "omnibus" budget legislation that on Jan. 26 he sent a letter to Office of Management and Budget Director Jacob Lew in which he writes that he's "convinced that the new legislation will have serious, unintended consequences for the nation's research enterprise." Speaking at the recent American Associ

Written byEugene Russo
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

The following is a preliminary outline of some of the major points of the COSEPUP report due to be released Feb. 17 at a public briefing in the Foundry Building, 1055 Thomas Jefferson St. N.W., room 2004, Washington, D.C. They're taken from the comments of Mildred Dresselhaus, an MIT professor, former AAAS president, COSEPUP member, and report coauthor, who spoke Jan. 23 at the AAAS meeting in Anaheim, Calif. For more information, go to the Web site at www.nas.edu or call the NAS/NAE/IOM/NRC office of news and public information at (202) 334-2138. According to Industry Representatives: Although quantifying results of basic research is not always possible, industry nevertheless supports basic research; in the long run, it pays off and is beneficial to industry. Metrics must be simple, not easily manipulated, and able to drive "constructive behavior." For example, when using indicators such as the number of publications per researcher, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies